Letrozole

Chemical formula: C₁₇H₁₁N₅ Molecular mass: 285.303 g/mol PubChem compound: 3902

Therapeutic indications

Letrozole is indicated for:

Hormone receptor positive malignant neoplasm of breast

Population group: women, only adults (18 years old or older)

Adjuvant treatment of postmenopausal women with hormone receptor positive invasive early breast cancer.
Extended adjuvant treatment of hormone-dependent-invasive breast cancer in postmenopausal women who have received prior standard adjuvant tamoxifen therapy for 5 years.
First-line treatment in postmenopausal women with hormone-dependent advanced breast cancer.
Advanced breast cancer after relapse or disease progression, in women with natural or artificially induced postmenopausal endocrine status, who have previously been treated with anti-oestrogens.
Neo-adjuvant treatment of postmenopausal women with hormone receptor positive, HER-2 negative breast cancer where chemotherapy is not suitable and immediate surgery not indicated.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

2.5 mg once daily

Contraindications

Letrozole is contraindicated in the following cases:

Pregnancy

Lactation

< Previous: Overview

Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.